BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors

To analyze responsiveness of gastric cancer to PARP inhibitor, researchers exploited a gastroesophageal adenocarcinoma platform of patient-derived xenografts (PDX) and PDX-derived primary cells and selected ten PDXs with loss-of-function mutations in homologous recombination pathway genes.